EPS for AstraZeneca PLC (AZN) Expected At $0.44

March 23, 2018 - By Ellis Scott

 EPS for AstraZeneca PLC (AZN) Expected At $0.44

Analysts expect AstraZeneca PLC (NYSE:AZN) to report $0.44 EPS on April, 26.They anticipate $0.55 EPS change or 55.56 % from last quarter’s $0.99 EPS. AZN’s profit would be $1.09B giving it 19.41 P/E if the $0.44 EPS is correct. After having $1.30 EPS previously, AstraZeneca PLC’s analysts see -66.15 % EPS growth. The stock decreased 0.87% or $0.3 during the last trading session, reaching $34.17. About 3.78M shares traded. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since March 23, 2017 and is uptrending. It has outperformed by 2.75% the S&P500.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 17 have Buy rating, 0 Sell and 9 Hold. Therefore 65% are positive. AstraZeneca plc (ADR) had 45 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Leerink Swann with “Market Perform” on Tuesday, February 6. The stock of AstraZeneca PLC (NYSE:AZN) has “Neutral” rating given on Monday, May 15 by Credit Suisse. The rating was maintained by Piper Jaffray on Wednesday, August 9 with “Buy”. Oddo & Cie upgraded the shares of AZN in report on Tuesday, January 26 to “Top Pick” rating. The rating was upgraded by Morgan Stanley on Tuesday, December 1 to “Overweight”. Liberum Capital downgraded the stock to “Hold” rating in Thursday, September 14 report. The stock has “Buy” rating by Jefferies on Monday, September 12. The stock of AstraZeneca PLC (NYSE:AZN) earned “Buy” rating by Bryan Garnier & Cie on Friday, September 18. The stock has “Buy” rating by Deutsche Bank on Monday, September 14. The firm has “Overweight” rating by JP Morgan given on Friday, December 29.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $84.89 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 28.84 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.